The present invention relates to new polymorphs of LXRP agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRP agonist, as well as methods of treating cancer including administration of a formulation including an LXRP agonist to a subject in need thereof.